Antimalarial Agent
ChemicalBook > CAS DataBase List > Atovaquone

Atovaquone

Antimalarial Agent
Product Name
Atovaquone
CAS No.
95233-18-4
Chemical Name
Atovaquone
Synonyms
trans-2-[4-(4-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione;2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthalenedione;Acuvel;BW-566C; 566C80;Wellvone;BW-566C-80;Atavaquone;ATOVAQUONE;Atorvaquone
CBNumber
CB4383893
Molecular Formula
C22H19ClO3
Formula Weight
366.84
MOL File
95233-18-4.mol
More
Less

Atovaquone Property

Melting point:
216-2190C
Boiling point:
535.0±50.0 °C(Predicted)
Density 
1.349±0.06 g/cm3(Predicted)
storage temp. 
2-8°C
solubility 
DMSO: >10mg/mL
form 
powder
pka
5.01±0.10(Predicted)
color 
yellow
λmax
494nm(aq. Buffer)(lit.)
Merck 
14,866
InChIKey
KUCQYCKVKVOKAY-CTYIDZIISA-N
CAS DataBase Reference
95233-18-4(CAS DataBase Reference)
More
Less

Safety

Hazard Codes 
N
Risk Statements 
50/53
Safety Statements 
60-61
RIDADR 
3077
WGK Germany 
3
RTECS 
QJ5616500
HS Code 
29147000
Hazardous Substances Data
95233-18-4(Hazardous Substances Data)
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H413May cause long lasting harmful effects to aquatic life

Precautionary statements

P273Avoid release to the environment.

P501Dispose of contents/container to..…

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
A7986
Product name
Atovaquone
Purity
≥98% (HPLC)
Packaging
10mg
Price
$79.5
Updated
2024/03/01
Sigma-Aldrich
Product number
1044651
Product name
Atovaquone
Purity
United States Pharmacopeia (USP) Reference Standard
Packaging
200mg
Price
$174.4
Updated
2024/03/01
TCI Chemical
Product number
A2545
Product name
Atovaquone
Purity
>98.0%(HPLC)(T)
Packaging
1g
Price
$420
Updated
2024/03/01
TCI Chemical
Product number
A2545
Product name
Atovaquone
Purity
>98.0%(HPLC)(T)
Packaging
200mg
Price
$121
Updated
2024/03/01
Cayman Chemical
Product number
23802
Product name
Atovaquone
Purity
≥98%
Packaging
5mg
Price
$36
Updated
2024/03/01
More
Less

Atovaquone Chemical Properties,Usage,Production

Antimalarial Agent

The hydroxynaphthoquinone atovaquone, which exhibits antimalarial and anti-Pneumocystis activity, is an electron transport inhibitor that causes depletion of the ATP pool. The primary effect is on the iron flavoprotein dihydro-orotate dehydrogenase, an essential enzyme in the production of pyrimidines. Mammalian cells are able to avoid undue toxicity by use of preformed pyrimidines. Dihydro-orotate dehydrogenase from Plasmodium falciparum is inhibited by concentrations of atovaquone that are very much lower than those needed to inhibit the Pneumocystis enzyme, raising the possibility that the antimicrobial consequences might differ in the two organisms. Although atovaquone was originally developed as a monotherapy for malaria, high level resistance readily emerges in Plasmodium falciparum when the drug is used alone. Consequently, atovaquone is now combined with proguanil.

Description

Atovaquone is an orally active antiprotozoal agent indicated for patients with mild to moderate AIDS-associated Pneumocystis carinii pneumonia who are intolerant to the fist-line therapy of trimethoprim-sulfamethoxazole. It is also under investigation as a treatment for malaria and AIDS-associated toxoplasmosis.

Chemical Properties

Yellow to Orange Crystalline Solid

Originator

Wellcome (United Kingdom)

Uses

Hydroxynaphthoquinone derivative that inhibits mitochondrial electron transport. Antipneumocystic

Uses

beta-adrenergic blocker

Uses

Atovaquone inhibits the cytochrome bc(1) complex via interactions with the Rieske iron-sulfur protein and cytochrome b in the ubiquinol oxidation pocket. In addition to its use as a treatment for toxoplasmosis, atovaquone has antimalarial properties and prevents pneumocystis pneumonia post-renal transplant.

Definition

ChEBI: A naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position.

Indications

Atovaquone is a naphthoquinone whose mechanism of action involves inhibition of the mitochondrial electron transport system in the protozoa. Malaria parasites depend on de novo pyrimidine biosynthesis through dihydroorotate dehydrogenase coupled to electron transport. Plasmodia are unable to salvage and recycle pyrimidines as do mammalian cells.
Atovaquone is poorly absorbed from the gastrointestinal tract, but absorption is increased with a fatty meal. Excretion of the drug, mostly unchanged, occurs in the feces.The elimination half-life is 2 to 3 days. Low plasma levels persist for several weeks. Concurrent administration of metoclopramide, tetracycline, or rifampin reduces atovaquone plasma levels by 40 to 50%.
Atovaquone has good initial activity against the blood but not the hepatic stage of P. vivax and P. ovale malaria parasites. It is effective against erythrocytic and exoerythrocytic P. falciparum, and therefore, daily suppressive doses need to be taken for only 1 week upon leaving endemic areas.When used alone, it has an unacceptable (30%) rate of recrudescence and selects for resistant organisms. It and proguanil are synergistic when combined and no atovaquone resistance is seen. This combination (Malarone) is significantly more effective than mefloquine, amodiaquine, chloroquine, and combinations of chloroquine, pyrimethamine, and sulfadoxine. In addition to using the combination of atovaquone and proguanil for the treatment and prophylaxis of P. falciparum malaria, atovaquone is also used for the treatment and prevention of P. carinii pneumonia and babesiosis therapy.
Atovaquone is well tolerated and produces only rare instances of nausea, vomiting, diarrhea, abdominal pain, headache, and rash of mild to moderate intensity.

Manufacturing Process

Preparation of intermediate 4-(4-chlorophenyl)cyclohexane-1-carboxylic acid was needed at first. It was made as follows: acetyl chloride (30 g), aluminium chloride (60 g) in carbon disulfide (120 ml) were stirred at -50°C. Cyclohexen (30 g) previously cooled to -50°C was added dropwise during 10 minutes and the mixture was stirred for 60 minutes at -50°C. The solvent was decanted and 300 ml chlorobenzene was added, the so-obtained solution heated at 40°C for 3 hours with stirring, poured onto a mixture of ice and concentrated hydrochloric acid and the organic layer washed with 2 M HCl, 2 M NaOH and water, dried over anhydrous Na2SO4. The product was distilled in vacuo, the fraction boiling at 140°-154°C (0.1 mm Hg) collected, diluted with an equal volume of petroleum ether, cooled to -6°C and a stream of nitrogen gas bubbled through.
3.1 g above obtained hexahydroacetophenone was dissolved in dioxan (15 ml) and the fresh preparated hypobromite (8 ml) in a solution of NaOH (6.2 g) in water (42 ml) at 0°C was added at below 20°C. The mixture was stirred at ambient temperature for 6 hours then allowed to stand overnight. Excess hypobromite was destroyed with sodium metabisulphite, cooled and then acidified to give a colourless solid. It was filtered off, washed with water, dried and recrystallysed from ethanol to give 4-(4-chlorophenyl)cyclohexane-1- carboxylic acid, m.p. 254°-256°C. A mixture of this acid, 2-chloro-1,4- naphthoquinone and silver nitrate was added to ammonium persulfate to give the corresponding naphthoquinone which was saponificated with KOH and was yielded 2-trans-4-(p-chlorophenyl)cyclohexyl)-3-hydroxy-1,4 naphthoquinone, m.p. 216°-219°C, shown by NMR to be the pure trans isomer.

brand name

Mepron (GlaxoSmithKline).

Therapeutic Function

Antiprotozoal

Antimicrobial activity

It is active against erythrocytic, liver and sexual stages of malaria parasites. It shows synergy with proguanil and tetracyclines in vitro. It is also active against Babesia spp. and both tachyzoites and cysts of Tox. gondii. Pn. jirovecii is sensitive in vitro at 0.1–3.0 mg/L and high doses are effective in the rat.

Acquired resistance

Point mutations on parasite cytochrome b, in particular at codon 268, cause resistance and readily occur when the drug is used alone. The rapid selection of resistance led to the development of the synergistic combination with proguanil. Failure of Pn. jirovecii prophylaxis has also been associated with cytochrome b mutations.

General Description

Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Atovaquone belongs to the class of naphthoquinones with a broad-spectrum activity against parasitic infections including malaria, toxoplasmosis and Pneumocystis pneumonia. It is a potent antiprotozoal compound which aids in collapsing the mitochondrial membrane potential in a malaria parasite.

Pharmaceutical Applications

A hydroxynaphthoquinone. Available as the trans isomer (which is more active than the cis form) for oral use. It is insoluble in water.

Biochem/physiol Actions

Atovaquone is an anti-protozoal mitochondrial electron transport inhibitor; Antimalarial; Antipneumocystic, and has also been used to treat toxoplasmosis. It is an analog of protozoan mitochondrial protein ubiquinone, and acts by inhibiting the cytochrome bc(1) complex via interactions with the Rieske iron-sulfur protein and cytochrome b in the ubiquinol oxidation pocket.

Mechanism of action

Atovaquone is thought to produce its antiparasitic action by virtue of its ability to inhibit the mitochondrial respiratory chain. More specifically, atovaquone is a ubiquinone reductase inhibitor, inhibiting at the cytochrome bc1 complex. This action leads to a collapse of the mitochondrial membrane potential. The compound shows stereospecific inhibition, with the trans isomer being more active than the cisisomer.

Pharmacokinetics

Oral absorption: Poor
Cmax 750 mg oral: 27 mg/L (steady state)
Plasma half-life: 70 h
Plasma protein binding: >99%
It is highly lipophilic and is poorly absorbed from the gastrointestinal tract following oral administration. Bioavailability is improved when administered with meals, particularly those with a high fat content. Steady-state plasma concentrations are up to 50% lower in AIDS patients than in asymptomatic HIV-positive cases and the elimination half-life is lower (55 h) in patients with AIDS. The concentration in CSF is <1% of the plasma level. Unlike some other naphthoquinones it is not metabolized by human liver microsomes. Combinations with co-trimoxazole (in HIV patients) and with proguanil plus artesunate in healthy adults did not produce any changes in atovaquone pharmacokinetics.

Clinical Use

3-[4-(4-Chlorophenyl)-cyclohexyl]-2-hydroxy-1,4-naphthoquinone(Mepron) is a highly lipophilic, water-insolubleanalog of ubiquinone 6, an essential component of the mitochondrialelectron transport chain in microorganisms. Thestructural similarity between atovaquone and ubiquinonesuggests that the former may act as an antimetabolite for thelatter and thereby interfere with the function of electrontransport enzymes.
Atovaquone was originally developed as an antimalarialdrug, but Plasmodium falciparum was found to developa rapid tolerance to its action. More recently, the effectivenessof atovaquone against P. carinii was discovered. Itis a currently recommended alternative to trimethoprimsulfamethoxazole(TMP-SMX) for the treatment and prophylaxisof PCP in patients intolerant to this combination.Atovaquone was also shown to be effective in eradicatingT. gondii in preclinical animal studies.
The oral absorption of atovaquone is slow and incomplete,in part because of the low water solubility of the drug.Aqueous suspensions provide significantly better absorptionthan do tablets. Food, especially if it has a high fat content,increases atovaquone absorption. Significant enterohepaticrecycling of atovaquone occurs, and most (nearly 95%) ofthe drug is excreted unchanged in the feces. In vivo, atovaquoneis largely confined to the plasma, where it is extensivelyprotein bound ( 99.9%). The half-life of the drugranges from 62 to 80 hours. The primary side effect is gastrointestinalintolerance.

Clinical Use

Pn. jirovecii pneumonia; alternative therapy for mild to moderate illness (prophylaxis and treatment)
Prophylaxis and treatment of malaria in combination with proguanil
It has also been used in cerebral toxoplasmosis in AIDS patients and in a few cases of human babesiosis.

Side effects

Most clinical trials of atovaquone alone have involved patients with AIDS in whom adverse effects are often difficult to detect; however, more than 20% reported fever, nausea, diarrhea and rashes. There were limited changes in hepatocellular function. In malaria, in combination with proguanil, there are few reported side effects.

Veterinary Drugs and Treatments

Atovaquone (with azithromycin) appears effective in treating dogs with Babesia gibsoni (Asian genotype) infections, particularly in dogs not immunosuppressed or splenectomized. Atovaquone may be of benefit for treating pneumocystosis in dogs, but it is considered second line therapy after potentiated sulfonamides. Atovaquone (with azithromycin) may be of benefit in treating Cytauxzoon felis infections in cats (research is in progress at the time of writing).

Drug interactions

Potentially hazardous interactions with other drugs
Antibacterials: avoid with rifabutin, concentration of both drugs reduced; avoid with rifampicin, concentration reduced and rifampicin concentration increased; concentration reduced by tetracycline.
Antivirals: concentration reduced by efavirenz - avoid; concentration of indinavir possibly reduced; concentration of zidovudine increased.
Metoclopramide: significant reduction in plasma atovaquone levels.

Metabolism

Atovaquone is poorly absorbed from the GI tract because of its poor water solubility and high fat solubility, but the absorption can be significantly increased if taken with a fat-rich meal. The drug is highly bound to plasma protein (94%) and does not enter the CNS in significant quantities. It is not significantly metabolized in humans and is exclusively eliminated in feces via the bile.

Atovaquone Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Atovaquone Suppliers

Shanghai Gukang Biotechnology Co., LTD
Tel
13564510648
Fax
021-54301252
Email
info@kanghaopharm.com
Country
China
ProdList
113
Advantage
58
Wuhan canos Technology Co., Ltd
Tel
027-83238443 15327105076
Fax
027-83238443
Email
926254131@qq.com
Country
China
ProdList
3010
Advantage
58
Condice Chemical (Hubei) Co., Ltd.
Tel
18064039730
Email
3127859172@qq.com
Country
China
ProdList
2828
Advantage
58
Wuhan Wiseman Bioengineering Co.,Ltd
Tel
027-59506022 13419526507
Fax
027-59506022
Email
13419526507@163.com
Country
China
ProdList
2985
Advantage
58
Wuhan Linglingjiu Biotechnology Co., Ltd
Tel
15623309010
Email
1287744812@qq.com
Country
China
ProdList
1658
Advantage
58
Hubei wei shi reagent group ltd., company
Tel
027-59105166 13125137732
Email
2853863890@qq.com
Country
China
ProdList
3310
Advantage
58
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Fax
86-10-82849933
Email
jkinfo@jkchemical.com
Country
China
ProdList
94657
Advantage
76
Chembest Research Laboratories Limited
Tel
+86-21-20908456
Fax
021-58180499
Email
sales@BioChemBest.com
Country
China
ProdList
6005
Advantage
61
TCI (Shanghai) Development Co., Ltd.
Tel
021-67121386
Fax
021-67121385
Email
Sales-CN@TCIchemicals.com
Country
China
ProdList
24529
Advantage
81
Energy Chemical
Tel
021-021-58432009 400-005-6266
Fax
021-58436166
Email
sales8178@energy-chemical.com
Country
China
ProdList
44688
Advantage
61
Wuhan Chemwish Technology Co., Ltd
Tel
86-027-67849912
Fax
86-027-87531808
Email
sales@chemwish.com
Country
China
ProdList
35896
Advantage
56
Adamas Reagent, Ltd.
Tel
400-6009262 16621234537
Fax
021-64823266
Email
chenyj@titansci.com
Country
China
ProdList
14103
Advantage
59
Nanjing Chemlin Chemical Co., Ltd
Tel
025-83697070
Fax
+86-25-83453306
Email
info@chemlin.com.cn
Country
China
ProdList
19182
Advantage
64
Chemsky(shanghai)International Co.,Ltd.
Tel
021-50135380
Email
shchemsky@sina.com
Country
China
ProdList
32321
Advantage
50
XiaoGan ShenYuan ChemPharm co,ltd
Tel
15527768850
Email
1791901229@qq.com
Country
China
ProdList
8835
Advantage
52
Sinopharm Chemical Reagent Co,Ltd.
Tel
86-21-63210123
Fax
86-21-63290778 86-21-63218885
Email
sj_scrc@sinopharm.com
Country
China
ProdList
9815
Advantage
79
Spectrum Chemical Manufacturing Corp.
Tel
021-021-021-67601398-809-809-809 15221380277
Fax
021-57711696
Email
marketing_china@spectrumchemical.com
Country
China
ProdList
9658
Advantage
60
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
sales@meilune.com
Country
China
ProdList
4727
Advantage
58
Wuhan Haizheng Industry & Trade Development Co. Ltd
Tel
027-8866 0053/88660577/88660578
Fax
027-8899 1911
Country
China
ProdList
1073
Advantage
55
Shanghai T&W Pharmaceutical Co., Ltd.
Tel
+86 21 61551611
Fax
+86 21 50676805
Country
China
ProdList
9891
Advantage
58
Nanjing Norris-Pharm Technology Co., Ltd
Tel
13901585132
Fax
+86-25-52131256
Email
799750417@qq.com
Country
China
ProdList
8878
Advantage
55
Haoyuan Chemexpress Co., Ltd.
Tel
021-58950125
Fax
(86) 21-58955996
Email
info@chemexpress.com
Country
China
ProdList
7552
Advantage
61
9ding chemical ( Shanghai) Limited
Tel
4009209199
Fax
86-021-52271987
Email
sales@9dingchem.com
Country
China
ProdList
22514
Advantage
55
Shanghai Aladdin Bio-Chem Technology Co.,LTD
Tel
400-400-6206333 18521732826
Fax
021-50323701
Email
market@aladdin-e.com
Country
China
ProdList
25003
Advantage
65
Chengdu AstaTech Trading Co., Ltd./AstaTech (Chengdu) Pharma. Co., Ltd.
Tel
+86-28-85122536 85324413
Fax
+86-28-85326443
Email
market@astatech.cn
Country
China
ProdList
8026
Advantage
55
Guangzhou Isun Pharmaceutical Co., Ltd
Tel
020-39119399 18927568969
Fax
020-39119999
Email
isunpharm@qq.com
Country
China
ProdList
4674
Advantage
55
Nanjing Sunlida Biological Technology Co., Ltd.
Tel
025-57798810
Fax
025-57019371
Email
sales@sunlidabio.com
Country
China
ProdList
3239
Advantage
55
TargetMol Chemicals Inc.
Tel
021-021-33632979 15002134094
Fax
021-33632979
Email
marketing@targetmol.com
Country
China
ProdList
7783
Advantage
58
Conier Chem & Pharma Co.,Ltd,
Tel
023-62879767 13996269627;
Fax
+86-28-84559521
Email
sales@conier.com
Country
China
ProdList
299
Advantage
56
Wuhan DKY Technology Co.,Ltd.
Tel
27-81302488 18007166089
Fax
027-81302088
Email
info@dkybpc.com
Country
China
ProdList
1672
Advantage
58
Bide Pharmatech Ltd.
Tel
400-164-7117 13681763483
Fax
+86-21-61629029
Email
product02@bidepharm.com
Country
China
ProdList
41462
Advantage
60
ChemStrong Scientific Co.,Ltd
Tel
0755-0755-66853366 13670046396
Fax
0755-28363542
Email
sales@chem-strong.com
Country
China
ProdList
18070
Advantage
56
Wuhan Dahua Pharmaceutical Co., Ltd.
Tel
027-59262863 13277907145 3091977954
Fax
027-59420980
Country
China
ProdList
4943
Advantage
58
Shanghai YuLue Chemical Co., Ltd.
Tel
021-60345187 13671753212
Fax
021-34702061
Email
lzz841106@aliyun.com
Country
China
ProdList
10274
Advantage
55
Shanghai Xingui Biotechnology Co., Ltd.
Tel
17501653713
Email
xingui2022@126.com
Country
China
ProdList
10028
Advantage
58
Shanghai Macklin Biochemical Co.,Ltd.
Tel
15221275939 15221275939
Fax
021-50706099
Email
shenlinxing@macklin.cn
Country
China
ProdList
16166
Advantage
55
Shanghai Kewel Chemical Co., Ltd.
Tel
021-64609169 18901607656
Fax
021-64609160
Email
greensnown@163.com
Country
China
ProdList
9906
Advantage
50
Hangzhou J&H Chemical Co., Ltd.
Tel
0571-+86-571-87396432
Fax
0571-87396431
Email
sales@jhechem.com
Country
China
ProdList
11578
Advantage
59
Shanghai Jovan Biochemical Technology Co. Ltd.
Tel
+86-021-61654350
Fax
+86-021-61654350
Email
1245958370@qq.com
Country
China
ProdList
2982
Advantage
50
AdooQ Bioscience CHINA
Tel
025-58849295 18951903616;
Fax
025-68650336
Email
info@adooq.cn
Country
China
ProdList
2990
Advantage
60
Hotechem Shanghai Co., Ltd.,
Tel
021-34621078 13120882795
Fax
021-34622517
Email
465106944@qq.com
Country
China
ProdList
856
Advantage
56
Hubei Jusheng Technology Co.,Ltd
Tel
027-59599241 18871490274
Fax
027-59599241
Email
1400878000@qq.com
Country
China
ProdList
9958
Advantage
58
Chizhou Kailong Import and Export Trade Co., Ltd.
Tel
Fax
-
Email
xg01_gj@163.com
Country
China
ProdList
9484
Advantage
50
Sigma-Aldrich
Tel
021-61415566 800-8193336
Email
orderCN@merckgroup.com
Country
China
ProdList
51456
Advantage
80
Shanghai Synchem Pharma Co., ltd
Tel
21-619849051-1 18521059765
Email
synchempharma@aliyun.com
Country
China
ProdList
6464
Advantage
55
Artis Biotech Co. Ltd.
Tel
0575-18780151478 18582380095
Fax
0575-89298961
Email
sales@artisbio.com
Country
China
ProdList
3044
Advantage
58
Guangzhou QiYun Biotechnology Co., Ltd.
Tel
020-61288194 61288195
Fax
020-61288700
Email
505721671@qq.com
Country
China
ProdList
3866
Advantage
58
Shanghai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847; 18021002903
Fax
QQ:3008007432
Email
3008007409@qq.com
Country
China
ProdList
27313
Advantage
60
Shanghai QianYan Bio-technology Co., Ltd
Tel
02781293128
Email
orders@biochemsafebuy.com
Country
China
ProdList
9923
Advantage
55
parabiochem
Tel
025-83453382-8005
Fax
025-83453382
Email
sale@parabiochem.com
Country
China
ProdList
9595
Advantage
55
More
Less

View Lastest Price from Atovaquone manufacturers

Hebei Weibang Biotechnology Co., Ltd
Product
Atovaquone 95233-18-4
Price
US $0.00/KG
Min. Order
1KG
Purity
99%
Supply Ability
100 MT
Release date
2024-11-14
Hebei Weibang Biotechnology Co., Ltd
Product
Atovaquone 95233-18-4
Price
US $0.00-0.00/KG
Min. Order
1KG
Purity
99%
Supply Ability
500000kg
Release date
2024-10-24
Hebei Fengjia New Material Co., Ltd
Product
Atovaquone 95233-18-4
Price
US $30.00/kg
Min. Order
1kg
Purity
0.99
Supply Ability
100 tons
Release date
2024-08-09

95233-18-4, AtovaquoneRelated Search:


  • trans-2-[4-(4-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione
  • 3-Hydroxy-2-[4β-(4-chlorophenyl)cyclohexan-1α-yl]naphthalene-1,4-dione
  • Atovaquone (200 mg)
  • Atovaquone, USP
  • 1,4-Naphthalenedione, 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-
  • Atavaquone
  • Atovaquone for system suitability
  • 566C80
  • BW-566C
  • BW-566C-80
  • Wellvone
  • ATOVAQUONE
  • 2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthalenedione
  • Atovaquone-D4
  • Acuvel
  • Atavaquone-d4
  • Atorvaquone
  • Atovaquone &gt
  • Atovaquone CRS
  • Atovaquone for system suitability CRS
  • 2-[trans-4-(4-Chlorophenyl)cyclohexyl]-3-hydroxynaphthalene-1,4-dione
  • Atovaquone USP/EP/BP
  • Atovaquone D4Q: What is Atovaquone D4 Q: What is the CAS Number of Atovaquone D4 Q: What is the storage condition of Atovaquone D4 Q: What are the applications of Atovaquone D4
  • AtovaquoneQ: What is Atovaquone Q: What is the CAS Number of Atovaquone Q: What is the storage condition of Atovaquone Q: What are the applications of Atovaquone
  • Atovaquone (1044651)
  • Atorvaquinone
  • 95233-18-4
  • 953-233-18-4
  • 95233018-4
  • 953233-18-4
  • C22H15ClO3D4
  • C22H19O3Cl
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • LEVATOL
  • Heterocycles
  • Coronavirus